tradmap

IPSC Earnings Century Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$10 -$5 $0 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $55M $109M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$137M -$68M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 $0 $1 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $55M $109M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$39M $19M $77M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–29 of 29
Q2 20262026-06-30-0.172026-08-1210-Q
Q1 20262026-03-31-0.112026-05-1310-Q
Q4 2025 (derived)2025-12-31-0.252026-03-1210-K
FY 20252025-12-31-0.142026-03-1210-K
Q3 20252025-09-30-0.402025-11-1310-Q
Q2 20252025-06-30-0.382025-08-1410-Q
Q1 20252025-03-310.892025-05-1510-Q
Q4 2024 (derived)2024-12-31-0.412025-03-1910-K
FY 20242024-12-31-1.612025-03-1910-K
Q3 20242024-09-30-0.372024-11-0510-Q
Q2 20242024-06-30-0.382024-08-0810-Q
Q1 20242024-03-31-0.45——
Q4 2023 (derived)2023-12-31-0.662024-03-1410-K
FY 20232023-12-31-2.302024-03-1410-K
Q3 20232023-09-30-0.552023-11-0910-Q
Q2 20232023-06-30-0.562023-08-0910-Q
Q1 20232023-03-31-0.532023-05-1110-Q
Q4 2022 (derived)2022-12-31-1.232023-03-1610-K
FY 20222022-12-31-2.962023-03-1610-K
Q3 20222022-09-30-0.532022-11-1010-Q
Q2 20222022-06-30-0.542022-08-1110-Q
Q1 20222022-03-31-0.662022-05-1610-Q
Q4 2021 (derived)2021-12-310.852022-03-1710-K
FY 20212021-12-31-3.952022-03-1710-K
Q3 20212021-09-30-0.482021-11-1010-Q
Q2 20212021-06-30-1.93——
Q1 20212021-03-31-2.39——
FY 20202020-12-31-9.55——
Q3 20202020-09-30-1.75——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.